[TECHNOLOGY OPPORTUNITY 1998-006]

<< Back to Life Sciences

Methods of Treating a CNS Disorder Using N,N-Dichlorinated Amino Acids and Derivatives
1998-006

Description:
Researchers at Queen's University have achieved high levels of BBB permeability with chlorinated taurine a critical omega amino acid for normal brain function. Chlorinated taurine reverts to taurine within the CNS. Experiments with rats provide evidence that administration of dichlorotaurine attenuates the pathological consequences of excessive glutamate release, which is known to occur under clinical conditions such as epilepsy, intractable pain disorders, Huntington's Disease, Parkinson's Disease and abnormalities associated with CNS trauma. Dichlorination with other omega amino acids such as homotaurine, GABA and l-leucine was also achieved.

Commercial Status:
US Patent No. 6,451,761 issued on September 17, 2002 granting broad method of treatment claims:
Claim 1.: A method treating a CNS disorder in a subject in need of such treatment, the method comprising administering to the subject an effective amount of an N,N-dichlorinated amino acid, peptide, peptidomimetic, or amine, such that a CNS disorder is treated.

Contact:
Anne Vivian-Scott,
Director, Commercial Development
PARTEQ Innovations
(613) 533 2342
avivianscott@parteqinnovations.com